Answers are grounded in this paper and cite their sources.
Review summarizes advancements in therapies and biomarkers for graft-versus-host disease after stem cell transplantation, highlighting critical findings.
Graft-versus-host disease (GVHD) remains a leading cause of non-relapse mortality after allogeneic hematopoietic stem cell transplantation (HSCT). This review provides a concise overview of the clinical spectrum of GVHD, including classical acute GVHD (aGVHD), chronic GVHD (cGVHD), and overlap syndromes as defined by the NIH Consensus Criteria. We summarize key advances in precision diagnostics, including the ST2/REG3α MAGIC biomarker panel, novel B-cell subsets (cGPS), which derive from a CD27+CD86+CD20- B-cell subpopulation, and transcriptomic profiling using single-cell RNA sequencing (scRNA-seq) and plasma cell-free RNA (cfRNA). We also examine extracellular vesicles and loss of gut microbiota diversity as critical drivers of pathogenesis. Finally, we analyze the current therapeutic landscape, distinguishing between 2024 prophylaxis recommendations and newly approved treatments for steroid-refractory disease.
No takes yet. Share an insight, caveat, or question.
Cui et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: